The Trouble With List Prices
This week, the RAND Corporation issued a new report highlighting that US list prices on insulin are 8.1 times higher than [...]
ICER Launches Customizable COVID-19 Cost-Effectiveness Model
The Institute for Clinical and Economic Review (ICER) announced the launch of a cloud-based platform that allows customization of model [...]
ConcertAI Launches CancerLinQ, An Oncology-focused Set of COVID-19 Resources
ConcertAI recently launched CancerLinQ Discovery, a set of oncology-focused COVID-19 resources aimed at supporting the needs of providers, innovators, and [...]
AstraZeneca Walks Back On its COVID-19 ‘No-Profit’ Pledge
Among the many pharma companies racing to develop a safe, effective vaccine for COVID-19, AstraZeneca stands out for its pledge [...]
Increasing Transparency in HEOR Through the Real-World Evidence (RWE) Transparency Initiative
Due to the funding or execution of studies by industry stakeholders and disagreements over methodological approaches, establishing and maintaining trust [...]
Dr. William Morice on Applying RWE to COVID-19 diagnostics
One of the most critical pieces of the COVID-19 puzzle is diagnostic testing that enables rapid diagnosis and treatment of [...]
PCORI’s Research Scope Expanded to Include Cost Outcomes
The Patient-Centered Outcomes Research Institute (PCORI) was created by the Affordable Care Act (ACA) in 2010. Since then, the institute [...]
Access Market Intelligence’s Specialty Pharmacy Database Now Available
Access Market Intelligence recently released its Specialty Pharmacy Database (SPD) which provides the industry’s most comprehensive, continually updated database on [...]
AMCP CEO Susan Cantrell Comments On Supreme Court Case
In commenting on Rutledge v. The Pharmaceutical Care Management Association, scheduled to be argued before the US Supreme Court yesterday, [...]
Enhancing RWE through Natural History Studies
Deploying RWE-analyses is not just a simple matter of having sufficient statistical knowledge. There are a variety of RWE methodologies [...]
Despite Limitations, Claims Data Still Useful in Fight Against COVID-19
The use of healthcare claims data in studying infectious disease has historically been rather limited. There are many other sources [...]
AMCP 2021’s Call for Poster Abstracts Now Open
AMCP invites submissions for abstracts to be presented at AMCP 2021 in the spring. Don’t miss your chance to share [...]
How Will Innovation Value be Redefined in 2021?
The health policy landscape will most certainly be altered in 2021 as a result of the US Presidential election. No [...]
Personalized Medicine Coalition Takes Aim at Setting Patient-centered Research Agenda
The Personalized Medicine Coalition (PMC) released a new patient-centered research agenda for personalized medicine defining 45 research questions across nine [...]
[Webinar] Cannabis Research to Reinforce Formulary Coverage Decisions
Cannabis as medicine has generated a tremendous amount of interest in the scientific community. It has also generated a tremendous [...]
COVID-19 and Prescription Utilization
The stay-at-home orders and economic uncertainty brought about by COVID-19 has impacted medication adherence and how patients manage their health. [...]
How HEOR Professionals Can Be Force Multipliers in the Fight Against COVID-19
US President Donald Trump and First Lady Melania Trump join the growing ranks of world leaders infected by COVID-19. It [...]
Onshoring Essential Drug Manufacturing is a Matter of National Security
Recently, FDA Commissioner Stephen Hahn and Deputy Commissioner Anand Shah wrote an op-ed stating that the COVID-19 pandemic exposed the [...]
ICER Weighs in on Fair Access to Prescription Drugs
Independent nonprofit Institute for Clinical and Economic Review (ICER) published a new white paper entitled “Cornerstones of ‘Fair’ Drug Coverage: [...]
Good Data Holds Tremendous Value for Patients
Innovative use of good data can lead to better patient care pathways and models of care. Collecting, collating, and assessing [...]
AMCP Partnership Forum: New Specialty Medication Benefit and Reimbursement Designs
One of the biggest challenges facing patients and payers is the rising cost of specialty drugs including gene therapies and [...]
How Government Permits Cross-subsidies to Inflate Healthcare Costs
Government often permits companies to overcharge one set of consumers in order to subsidize other consumers in a market-distorting phenomenon [...]
Syapse and FDA Leverage Real-World Data to Study Impact of COVID-19 on Cancer Patients
According to the National Cancer Institute, the COVID-19 pandemic has resulted in delays for cancer screening, diagnosis, and treatment, leading [...]
[Webinar] The Informative Bayesian: Meta-analytic Predictive (MAP) Priors
Real world data typically has a lot of missing information. This often requires imputation of missing values which is not [...]
Harnessing the Power of RWD in China
In 2018, China made the cultivation of healthcare big data a national priority. Such data represent a tremendous opportunity for [...]